Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

The present invention provides a method of preparing oxalic acid (H.sub.2C.sub.2O.sub.4), the method at least comprising the steps of: (a) providing a metal formate (HCO.sub.2M) containing stream, wherein the metal (M) of the metal formate (HCO.sub.2M) is a monovalent metal selected from the group consisting of Li, Na, K, Cs, Rb and a mixture thereof; (b) heating the metal formate (HCO.sub.2M) containing stream thereby obtaining a metal oxalate (M.sub.2C.sub.2O.sub.4) containing stream; (c) subjecting the metal oxalate (M.sub.2C.sub.2O.sub.4) containing stream to electrodialysis, thereby obtaining at least oxalic acid (M.sub.2C.sub.2O.sub.4) and a metal hydroxide (MOH).

The present invention provides a method of preparing oxalic acid (H.sub.2C.sub.2O.sub.4), the method at least comprising the steps of: (a) providing a metal formate (HCO.sub.2M) containing stream, wherein the metal (M) of the metal formate (HCO.sub.2M) is a monovalent metal selected from the group consisting of Li, Na, K, Cs, Rb and a mixture thereof; (b) heating the metal formate (HCO.sub.2M) containing stream thereby obtaining a metal oxalate (M.sub.2C.sub.2O.sub.4) containing stream; (c) subjecting the metal oxalate (M.sub.2C.sub.2O.sub.4) containing stream to electrodialysis, thereby obtaining at least oxalic acid (M.sub.2C.sub.2O.sub.4) and a metal hydroxide (MOH).

This invention relates to the field of plastic waste decomposition. More specifically, the invention comprises products obtained from the decomposition of plastic waste.

This invention relates to the field of plastic waste decomposition. More specifically, the invention comprises products obtained from the decomposition of plastic waste.

The present invention relates to a co-crystalline form of efinaconazole and a pharmaceutically acceptable coformer forming a co-crystalline phase. The present invention also relates to a method for preparing the co-crystalline form. The co-crystallization product of efinaconazole according to the present invention meets all requirements for use as an active ingredient of a pharmaceutical composition and is highly stable to heat and other one or more other ingredients of the composition. Therefore, the co-crystallization product of efinaconazole is suitable for use in the preparation of pharmaceuticals. In addition, the method of the present invention enables the preparation of the co-crystallization product of efinaconazole in a simple and easy manner on a commercial scale.

The present invention is directed to stable lyophilisates comprising 5,10-methylene-(6R)-tetrahydrofolic acid or a pharmaceutically acceptable salt thereof and a dicarboxylic acid, or a salt thereof, as well as, a processes of obtaining the same, and the use of such products.

The present invention provides freebase and salt forms, and compositions and methods thereof, useful for treating various conditions in which aldehyde toxicity is implicated in the pathogenesis by the administration of small molecule therapeutics acting as a scavenger for toxic aldehydes.

This invention relates to the field of contaminated plastic waste decomposition. More specifically, the invention comprises methods and systems to decompose contaminated plastic waste and transform it into value-added products.